Psychemedics Net Income 2012-2024 | PMD
Psychemedics net income from 2012 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
|
Psychemedics Annual Net Income (Millions of US $) |
|
|---|---|
| 2024 | $-2 |
| 2023 | $-4 |
| 2022 | $-1 |
| 2021 | $-1 |
| 2020 | $-4 |
| 2019 | $2 |
| 2018 | $5 |
| 2017 | $6 |
| 2016 | $7 |
| 2015 | $2 |
| 2014 | $3 |
| 2013 | $4 |
| 2012 | $3 |
| 2011 | $3 |
|
Psychemedics Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2024-12-31 | $0 |
| 2024-09-30 | $-1 |
| 2024-06-30 | $-1 |
| 2024-03-31 | $-1 |
| 2023-12-31 | $-1 |
| 2023-09-30 | $-2 |
| 2023-06-30 | $-1 |
| 2023-03-31 | $0 |
| 2022-12-31 | $-1 |
| 2022-09-30 | $0 |
| 2022-06-30 | $0 |
| 2022-03-31 | $0 |
| 2021-12-31 | $-2 |
| 2021-09-30 | $1 |
| 2021-06-30 | $0 |
| 2021-03-31 | $0 |
| 2020-12-31 | $-1 |
| 2020-09-30 | $-1 |
| 2020-06-30 | $-2 |
| 2020-03-31 | $0 |
| 2019-12-31 | $-1 |
| 2019-09-30 | $1 |
| 2019-06-30 | $1 |
| 2019-03-31 | $1 |
| 2018-12-31 | $1 |
| 2018-09-30 | $1 |
| 2018-06-30 | $1 |
| 2018-03-31 | $1 |
| 2017-12-31 | $2 |
| 2017-09-30 | $1 |
| 2017-06-30 | $1 |
| 2017-03-31 | $2 |
| 2016-12-31 | $2 |
| 2016-09-30 | $3 |
| 2016-06-30 | $2 |
| 2016-03-31 | $0 |
| 2015-12-31 | $0 |
| 2015-09-30 | $1 |
| 2015-06-30 | $0 |
| 2015-03-31 | $0 |
| 2014-12-31 | $1 |
| 2014-09-30 | $1 |
| 2014-06-30 | $1 |
| 2014-03-31 | $1 |
| 2013-12-31 | $1 |
| 2013-09-30 | $1 |
| 2013-06-30 | $1 |
| 2013-03-31 | $1 |
| 2012-12-31 | $0 |
| 2012-09-30 | $1 |
| 2012-06-30 | $1 |
| 2012-03-31 | $1 |
| 2011-12-31 | $0 |
| 2011-09-30 | $1 |
| 2011-06-30 | $1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $0.000B | $0.020B |
| Psychemedics Corporation provides testing services for the detection of abused substances through the analysis of hair samples. Their testing methods utilize a patented technology for performing immunoassays on enzymatically dissolved hair samples with confirmation testing by mass spectrometry. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fresenius SE (FSNUY) | Germany | $29.514B | 13.37 |
| Quest Diagnostics (DGX) | United States | $21.197B | 19.44 |
| Elanco Animal Health (ELAN) | United States | $11.500B | 24.35 |
| Encompass Health (EHC) | United States | $10.662B | 19.64 |
| DaVita (DVA) | United States | $10.023B | 13.82 |
| Chemed (CHE) | United States | $5.639B | 19.57 |
| Option Care Health (OPCH) | United States | $4.553B | 18.71 |
| RadNet (RDNT) | United States | $4.302B | 142.13 |
| LifeStance Health (LFST) | United States | $2.495B | 320.00 |
| Addus HomeCare (ADUS) | United States | $1.719B | 16.61 |
| Astrana Health (ASTH) | United States | $1.536B | 31.40 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.353B | 12.20 |
| U.S Physical Therapy (USPH) | United States | $1.157B | 29.19 |
| Pennant (PNTG) | United States | $1.072B | 31.31 |
| Daxor (DXR) | United States | $0.048B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.032B | 0.00 |